Drug groups [BR:br08330]
Antineoplastic
DG01918 Tyrosine kinase inhibitor
DG03136 ALK inhibitor
DG02996 Ensartinib
D11356 Ensartinib hydrochloride
Metabolizing enzyme substrate
DG01633 CYP3A/CYP3A4 substrate
DG02996 Ensartinib
D11356 Ensartinib hydrochloride
Target-based classification of drugs [BR:br08310]
Protein kinases
Receptor tyrosine kinases (RTK)
ALK family
EML4-ALK [HSA_VAR:238v1]
D11356 Ensartinib hydrochloride (USAN)
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D11356
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D11356
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D11356
Drug groups [BR:br08330]
Antineoplastic
DG01918 Tyrosine kinase inhibitor
DG03136 ALK inhibitor
DG02996 Ensartinib
Metabolizing enzyme substrate
DG01633 CYP3A/CYP3A4 substrate
DG02996 Ensartinib